Clinical Trials Browser

Thyroid Cancer, Papillary × Vemurafenib × Clear all

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Phase 2 Recruiting

21 enrolled

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Phase 1 Completed

8 enrolled 8 charts

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Clinical Trials

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

DETERMINE

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers